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Prevention of Atrial Fibrillation by
Renin-Angiotensin System Inhibition
A Meta-Analysis
Markus P. Schneider, MD,* Tsushung A. Hua, PHD,† Michael Böhm, MD,‡
Kristian Wachtell, MD, PHD,§ Sverre E. Kjeldsen, MD, PHD, Roland E. Schmieder, MD*
Erlangen and Homburg, Germany; East Hanover, New Jersey; Copenhagen, Denmark;
and Ullevål, Norway
Objectives The authors reviewed published clinical trial data on the effects of renin-angiotensin system (RAS) inhibition for
the prevention of atrial fibrillation (AF), aiming to define when RAS inhibition is most effective.
Background Individual studies examining the effects of RAS inhibition on AF prevention have reported controversial results.
Methods All published randomized controlled trials reporting the effects of treatment with angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers in the primary or secondary prevention of AF were included.
Results A total of 23 randomized controlled trials with 87,048 patients were analyzed. In primary prevention, 6 trials in
hypertension, 2 trials in myocardial infarction, and 3 trials in heart failure were included (some being post-hoc
analyses of randomized controlled trials). In secondary prevention, 8 trials after cardioversion and 4 trials as-
sessing the medical prevention of recurrence were included. Overall, RAS inhibition reduced the odds ratio for AF
by 33% (p  0.00001), but there was substantial heterogeneity among trials. In primary prevention, RAS inhibi-
tion was effective in patients with heart failure and those with hypertension and left ventricular hypertrophy but
not in post-myocardial infarction patients overall. In secondary prevention, RAS inhibition was often adminis-
tered in addition to antiarrhythmic drugs, including amiodarone, further reducing the odds for AF recurrence af-
ter cardioversion by 45% (p  0.01) and in patients on medical therapy by 63% (p  0.00001).
Conclusions This analysis supports the concept of RAS inhibition as an emerging treatment for the primary and secondary
prevention of AF but acknowledges the fact that some of the primary prevention trials were post-hoc analyses.
Further areas of uncertainty include potential differences among specific RAS inhibitors and possible interac-
tions or synergistic effects with antiarrhythmic drugs. (J Am Coll Cardiol 2010;55:2299–307) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.043e
d
d
h
r
c
K
G
P
r
I
S
a
M
Rtrial fibrillation (AF) is the most common cardiac arrhyth-
ia, causing substantial cardiovascular morbidity and mortality
1,2). New approaches for the prevention and treatment of AF
re needed, considering the limited efficacy and significant side
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AF and RAS Inhibition May 25, 2010:2299–307left atrial dilation and fibrosis, and
electrical remodeling, including
the shortening of atrial refractori-
ness (3). In addition, impaired he-
modynamic state, including vol-
ume changes, increased afterload
states, pre-hypertension, and frank
hypertensive disease, is thought to
play a significant role in triggering
AF (4).
More recently, there has been
an interest in the potential role of
renin-angiotensin system (RAS)
blockade for the prevention and
treatment of AF. Intriguingly, mice
with cardiac-restricted angiotensin-
converting enzyme expression have
ormally structured ventricles but exhibit severe atrial dilation
nd develop AF (5). In the atria of patients with chronic AF,
ncreased expression of angiotensin-converting enzyme and the
ngiotensin II type 1 receptor, as well as increased angiotensin
I-dependent activation of downstream signaling pathways
nvolved in fibrogenesis, have been found (6,7). In addition to
ffects on structural remodeling, angiotensin II affects electro-
hysiological properties of the myocardium and the pulmonary
eins. Recent data suggest that angiotensin II type 1 receptors
re located in close proximity to potassium channels within the
embrane (8) and that angiotensin II inhibits outward potas-
ium currents thought to be involved in the pathophysiology of
F (9).
Animal models of AF have shown that RAS blockade,
sing either an angiotensin-converting enzyme inhibitor
ACEI) or an angiotensin receptor blocker (ARB), has
eneficial effects on electrical remodeling (9,10) and on
tructural remodeling, in particular left atrial fibrosis and
ilation (11,12). In humans, the use of ACEIs was associ-
ted with less atrial fibrosis (13), and the blockade of
ngiotensin II has been shown to have beneficial effects on
lectrical remodeling in human atrial tissue (14). In addi-
ion, RAS inhibition has been extensively studied with
egard to its blood pressure–reducing properties as well as its
nown afterload-reducing effects by lowering central blood
ressure (15). Regarding the clinical effects of RAS inhibi-
ion, a substantial amount of human trial data have accumu-
ated. However, the results of the individual trials are conflict-
ng. We have therefore performed a meta-analysis and a
omprehensive review of the available data, aiming to more
learly define the conditions and circumstances in which RAS
lockade may be a promising preventive therapy.
ethods
tudy selection. A comprehensive search was conducted to
dentify all relevant human trials of treatment with ACEIs
r ARBs, reporting on new-onset or recurrent AF. PubMed
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
AF  atrial fibrillation
ARB  angiotensin
receptor blocker
CI  confidence interval
ECG  electrocardiography
MI  myocardial infarction
OR  odds ratio
RAS  renin-angiotensin
system
RCT  randomized
controlled trialas searched using the terms “angiotensin,” “angiotensin aeceptor blocker,” and “angiotensin converting enzyme,”
ndividual names in these drug classes, and “atrial fibrilla-
ion” using Boolean operators. In addition, relevant review
eports and the reference lists of retrieved reports were
earched for further potentially relevant studies. Only full
ublications in English were considered (no abstracts). Two
eviewers independently evaluated the retrieved reports,
hich were considered further if they reported on either
CEI or ARB treatment in comparison with placebo or
lternative therapy but were excluded if none of these
ontrol groups were present (e.g., excluding the recent
NTARGET [Ongoing Telmisartan Alone and in Com-
ination With Ramipril Global Endpoint Trial]). Any
iscordance between the reviewers was resolved by discus-
ion. For the main analysis, only reports including absolute
r percent rates of AF development or recurrence derived
rom prospective studies randomized for ACEI or ARB
reatment and alternative therapy or placebo were included.
n a subanalysis, we excluded those trials in which AF had
ot been a pre-specified end point (i.e., in which AF was
nalyzed post-hoc, which was the case in some of the
rimary prevention studies). For final sensitivity analysis of
ll data, the main analysis was repeated after the additional
nclusion of published nonrandomized observational studies
nd those in which initial randomization was not for ACEI
r ARB therapy (e.g., Palardy et al. [16]). Studies reporting
F rates in the context of cardiac surgery and in the context
f catheter ablation procedures were not included. The last
ollow-up observation was entered into these analyses, and
F rates and odds ratios (ORs) were calculated based on the
ntention-to-treat principle. In 1 study, the data from 2
ontrol arms were pooled (17). Two studies had separate
reatment arms with ACEIs and ARBs (18,19), which were
ither pooled for the analysis of effects of ACEIs and ARBs
ombined or taken as separate strata.
tatistical analysis. Meta-analysis was performed using
evMan version 4.2 for Windows (The Nordic Cochrane
entre, Copenhagen, Denmark). Statistical heterogeneity
cross the various trials was tested using the Q statistic, and
2 was calculated to quantify inconsistency among trials. A
andom-effects model was used to weight effect sizes by
ample size to calculate weighted mean effect sizes (20).
hese are presented as ORs with 95% confidence intervals
CIs). A value of p 0.05 (2-sided) was considered statistically
ignificant.
esults
f the identified studies, 23 were randomized for ACEI or
RB treatment or placebo or alternative therapy, while 5
ere not randomized (21–25) and 1 was randomized for
ntiarrhythmic drugs but not for ACEI or ARB treatment
16). The characteristics of all trials are summarized in
able 1. Our primary analysis included only those studies
andomized for ACEI or ARB treatment or placebo or
lternative therapy. These included a total of 87,048 pa-
Characteristics of Included StudiesTable 1 Characteristics of Included Studies
Study Patient Group
Study
Design n
Follow-Up
(Months) ACEI/ARB (Type) Comparator Drug Outcome End Point How AF Diagnosed
Primary prevention
Hypertension trials
Hansson et al. (CAPPP), 1999 (26) HTN RCT 10,915 73.2 Captopril Diuretic/BB All AF 2° end point Adverse event
Hansson et al. (STOP-2), 1999 (17) HTN RCT 6,303 60 Enalapril/lisinopril Diuretic/BB or CCB All AF 2° end point Adverse event
Wachtell et al. (LIFE), 2005 (37) HTN  LVH RCT 8,480 57.6 12 Losartan Atenolol New-onset AF 2° end point Yearly ECG
Salehian et al. (HOPE), 2007 (27) High risk  HTN RCT 8,335 54 Ramipril Placebo New-onset AF Post-hoc Biannual ECG
Schmieder et al. (VALUE), 2008 (30) HTN  high risk RCT 13,760 50.4 Valsartan Amlodipine New-onset AF 2° end point Yearly ECG
Yusuf et al. (TRANSCEND), 2008 (28) High risk  HTN (ACE intolerant) RCT 5,701 56 Telmisartan Placebo New-onset AF 2° end point Not stated
Post-MI
Pedersen et al. (TRACE), 1999 (32) Post-MI RCT 1,577 24–48 Trandolapril Placebo New-onset AF Post-hoc Regular ECG
Pizzetti et al. (GISSI-3), 2001 (31) Post-MI RCT 17,711 1.5 Lisinopril Placebo New-onset AF Post-hoc In-hospital ECG
Heart failure
Vermes et al. (SOLVD), 2003 (33) Heart failure RCT 374 34.8 12 Enalapril Placebo New-onset AF Post-hoc ECG and Holter monitoring
Ducharme et al. (CHARM), 2006 (34) Heart failure RCT 6,379 37.7 Candesartan Placebo New-onset AF 2° end point Adverse event
Maggioni et al. (Val-HeFT), 2005 (35) Heart failure RCT 4,395 23 Valsartan Placebo New-onset AF Post-hoc Adverse event
Secondary prevention
After cardioversion
Van den Berg et al., 1995 (43) Persistent AF  CHF RCT 18 1.5 Lisinopril Placebo Recurrence 1° end point Holter monitoring
Madrid et al., 2002 (47) Persistent AF RCT 154 2 Irbesartan No irbesartan Recurrence 1° end point Regular ECG
Ueng et al., 2003 (49) Persistent AF RCT 145 9 Enalapril No enalapril Recurrence 1° end point Regular ECG
Madrid et al., 2004 (48) Lone persistent AF RCT 60 7.3 Irbesartan No irbesartan Recurrence 1° end point ECG and Holter monitoring
Grecu et al., 2007 (50) Lone persistent AF RCT 36 12 Perindopril No perindopril Recurrence 1° end point Regular ECG
Tveit et al., 2007 (45) Persistent AF RCT 137 6 Candesartan Placebo Recurrence 1° end point ECG
Belluzzi et al., 2009 (51) Lone persistent AF RCT 62 36 Ramipril Placebo Recurrence 1° end point ECG and Holter monitoring
Disertori et al. (GISSI-AF), 2009 (44) Persistent AF RCT 1,442 12 Valsartan Placebo Recurrence 1° end point Telemonitoring
Van Noord et al., 2005 (25) Persistent AF OBS 107 1 ACEI No ACEI Recurrence NA Regular ECG
Fazio et al., 2007 (21) Paroxysmal and persistent AF OBS 187 24 ACEI No ACEI Recurrences 2 NA ECG
By medical therapy
Yin et al., 2006 (19) Lone paroxysmal AF RCT 177 24 Losartan or perindopril Placebo Recurrence 1° end point ECG and Holter monitoring
Fogari et al., 2006 (52) Paroxysmal AF RCT 222 12 Losartan Amlodipine Recurrence 1° end point ECG
Fogari et al., 2008 (18) Paroxysmal AF RCT 369 12 Valsartan or ramipril Atenolol Recurrence 1° end point ECG and Holter monitoring
Fogari et al., 2008 (53) Paroxysmal AF RCT 296 12 Valsartan Atenolol Recurrence 1° end point ECG
Palardy et al., 2008 (16) Paroxysmal AF RCT 401 15.6 5 ACEI or ARB* No ACEI or ARB Recurrence Post-hoc ECG
Hirayama et al., 2005 (22) Paroxysmal AF OBS 95 99.6 42 ACEI No ACEI Persistent AF NA ECG
Kawamura et al., 2007 (23) Paroxysmal and persistent AF OBS 125 24 ACEI or ARB No ACEI or ARB Recurrence NA ECG
Komatsu et al., 2008 (24) Paroxysmal AF OBS 58 43 18 Enalapril No enalapril Persistent AF NA Regular ECG
Observational studies are in italics. *The study by Palardy et al. (16) was initially randomized for amiodarone versus sotalol or propafenone and retrospectively compared for ACEI or ARB versus non-ACEI and non-ARB treatment.
ACEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; ARB  angiotensin receptor blocker; BB  beta-blocker; CAPPP  Captopril Prevention Project; CCB  calcium-channel blocker; CHARM  Candesartan in Heart Failure: Assessment of Reduction
in Mortality and Morbidity; CHF chronic heart failure; ECG electrocardiography; GISSI-AF Gruppo Italiano per lo Studio Della Sopravvivenza Nell’Infarto Miocardico–Atrial Fibrillation; GISSI-3 Gruppo Italiano per lo Studio Della Sopravvivenza Nell’Infarto Miocardico-3;
HOPE  Heart Outcomes Prevention Evaluation; HTN  arterial hypertension; LIFE  Losartan Intervention For Endpoint Reduction in Hypertension; LVH  left ventricular hypertrophy; MI  myocardial infarction; NA  not applicable; OBS  observational; 1°  primary;
RCT randomized controlled trial; STOP-2 Swedish Trial in Old Patients With Hypertension-2; TRACE Trandolapril Cardiac Evaluation; TRANSCEND Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease; 2° secondary;
Val-HeFT  Valsartan Heart Failure Trial; VALUE  Valsartan Antihypertensive Long-Term Use Evaluation.
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AF and RAS Inhibition May 25, 2010:2299–307ients: 53,494 in 6 hypertension trials (primary prevention),
9,288 in 2 trials after myocardial infarction (MI) (primary
revention), 11,148 in 3 heart failure trials (primary preven-
ion), 2,054 in 8 studies after cardioversion (secondary
revention), and 1,064 patients in 4 studies of medical
herapy for AF (secondary prevention). The effects of
CEIs were studied in 45,841 patients and the effects of
Review: ARB/ACE for Prevention of AF
Comparison: 01 ARB/ACE for Prevention of AF         
Outcome: 01 Atrial Fibrillation                     
lortnoCtnemtaerTydutS
N/nN/nyrogetac-busro
01 Hypertension Studies
 Hansson (CAPPP)          117/5456           135/5459      
 Hansson (STOP-2)         200/2088           357/4215      
 Wachtell (LIFE)          150/4298           221/4182      
 Salehian (HOPE)           86/4291            91/4044      
 Schmieder (VALUE)        252/6872           299/6888      
 Yusuf (TRANSCEND)        182/2844           180/2857      
Subtotal (95% CI) 25849              27645
Total events: 987 (Treatment), 1283 (Control)
Test for heterogeneity: Chi² = 17.98, df = 5 (P = 0.003), I² = 72.2%
Test for overall effect: Z = 1.39 (P = 0.17)
02 Post-MI studies
 Pedersen (TRACE)          22/790             42/787       
 Pizzetti (GISSI-3)       665/8865           721/8846      
Subtotal (95% CI) 9655               9633
Total events: 687 (Treatment), 763 (Control)
Test for heterogeneity: Chi² = 4.59, df = 1 (P = 0.03), I² = 78.2%
Test for overall effect: Z = 1.13 (P = 0.26)
03 Heart Failure studies
 Vermes (SOLVD)            10/186             45/188       
 Ducharme (CHARM)         177/3191           215/3188      
 Maggioni (Val-HeFT)      113/2205           174/2190      
Subtotal (95% CI) 5582               5566
Total events: 300 (Treatment), 434 (Control)
Test for heterogeneity: Chi² = 16.40, df = 2 (P = 0.0003), I² = 87.8%
Test for overall effect: Z = 2.48 (P = 0.01)
04 Post-cardioversion studies
 Van den Berg               2/7                7/11        
 Madrid                     9/79              22/75        
 Ueng                      18/70              32/75        
 Madrid 2                   8/30              14/30        
 Grecu                     10/16              16/20        
 Tveit                     48/68              45/69        
 Belluzzi                   3/31              10/31        
 GISSI-AF                 371/722            375/720       
Subtotal (95% CI) 1023               1031
Total events: 469 (Treatment), 521 (Control)
Test for heterogeneity: Chi² = 18.59, df = 7 (P = 0.010), I² = 62.3%
Test for overall effect: Z = 2.44 (P = 0.01)
05 Medical Therapy studies
 Yin                       25/118             24/59        
 Fogari 1                  13/111             39/111       
 Fogari 2                  42/246             46/123       
 Fogari 3                  28/148             48/148       
Subtotal (95% CI) 623                441
Total events: 108 (Treatment), 157 (Control)
Test for heterogeneity: Chi² = 2.45, df = 3 (P = 0.49), I² = 0%
Test for overall effect: Z = 6.73 (P < 0.00001)
Total (95% CI) 42732              44316
Total events: 2551 (Treatment), 3158 (Control)
Test for heterogeneity: Chi² = 100.83, df = 22 (P < 0.00001), I² = 78.2%
Test for overall effect: Z = 5.24 (P < 0.00001)
 0.1
 
Figure 1 Effect of RAS Inhibition on Occurrence of AF
Effect of angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blo
(hypertension, post-myocardial infarction [MI], and heart failure studies) and in sec
Prevention Project; CHARM  Candesartan in Heart Failure: Assessment of Reduc
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R of developing AF (primary and secondary prevention)
y 33% (OR: 0.67; 95% CI: 22% to 43%; p  0.00001)
Fig. 1). Similar benefits were observed when separately
onsidering ACEIs (OR: 0.64; 95% CI: 19% to 50%; p 
.0003) or ARBs (OR: 0.64; 95% CI: 22% to 48%; p 
.0001). However, treatment effects were different among
dnar(ROthgieW)modnar(RO om)
IC%59%IC%59
  6.39      0.86 [0.67, 1.11]        
  6.97      1.14 [0.95, 1.37]        
  6.73      0.65 [0.52, 0.80]        
  5.95      0.89 [0.66, 1.20]        
  7.06      0.84 [0.71, 1.00]        
  6.72      1.02 [0.82, 1.26]        
 39.82      0.89 [0.75, 1.05]
  3.99      0.51 [0.30, 0.86]        
  7.45      0.91 [0.82, 1.02]        
 11.45      0.72 [0.41, 1.27]
  2.80      0.18 [0.09, 0.37]        
  6.78      0.81 [0.66, 1.00]        
  6.44      0.63 [0.49, 0.80]        
 16.03      0.52 [0.31, 0.87]
  0.51      0.23 [0.03, 1.77]        
  2.22      0.31 [0.13, 0.73]        
  2.88      0.47 [0.23, 0.94]        
  1.55      0.42 [0.14, 1.23]        
  0.90      0.42 [0.09, 1.85]        
  2.80      1.28 [0.62, 2.63]        
  1.00      0.23 [0.06, 0.92]        
  6.77      0.97 [0.79, 1.20]        
 18.64      0.55 [0.34, 0.89]
  3.00      0.39 [0.20, 0.78]        
  2.92      0.24 [0.12, 0.49]        
  4.23      0.34 [0.21, 0.56]        
  3.91      0.49 [0.28, 0.83]        
 14.06      0.37 [0.27, 0.49]
100.00      0.67 [0.57, 0.78]
 0.5  1  2  5  10
reatment  Favors control
RB) treatment on the occurrence of atrial fibrillation (AF) in primary prevention
y prevention (post-cardioversion and medical therapy studies). CAPPP  Captopril
Mortality and Morbidity; CI  confidence interval; GISSI-AF  Gruppo Italiano per
Italiano per lo Studio Della Sopravvivenza Nell’Infarto Miocardico–3; HOPE 
tion in Hypertension; OR  odds ratio; RAS  renin-angiotensin system;
iac Evaluation; TRANSCEND  Telmisartan Randomized Assessment Study in
Trial; VALUE  Valsartan Antihypertensive Long-Term Use Evaluation. 0.2
Favors t
cker (A
ondar
tion in
Gruppo
Reduc
l Card
Failurendividual trials, as evidenced by a significant test for
h
e
t
c
P
A
a
t
1
n
(
T
H
(
d
W
o
L
H
t
t
r
P
t
A
i
o
H
i
t
I
M
r
l
O
f
d
e
p
a
n
H
i
s
t
w
m
V
e
O
i
3
n
g
S
p
s
w
C
S
a
r
O
r
A
m
T
S
F
v
f
p
B
t
p
c
t
c
h
d
A
S
p
p
o
a
t
n
s
i
e
p
e
o
a
e
w
r
fi
E
p
a
r
C
P
f
t
h
2303JACC Vol. 55, No. 21, 2010 Schneider et al.
May 25, 2010:2299–307 AF and RAS Inhibitioneterogeneity (p  0.00001). We therefore analyzed the
ffect of ACEI or ARB treatment separately in different
reatment populations, to more clearly define the clinical
onditions in which RAS inhibition is most effective.
rimary prevention. HYPERTENSION. Six trials compared
CEIs or ARBs with other agents for the treatment of
rterial hypertension. Overall, no significant reduction in
he OR for AF was detectable (OR: 0.89; 95% CI: 0.75 to
.05; p  0.17). However, there was significant heteroge-
eity among trials (chi-square test, p  0.003). CAPPP
Captopril Prevention Project) (26), STOP-2 (Swedish
rial in Old Patients With Hypertension-2) (17), the
OPE (Heart Outcomes Prevention Evaluation) study
27), and the recent TRANSCEND (Telmisartan Ran-
omized Assessment Study in ACE Intolerant Subjects
ith Cardiovascular Disease) (28) did not detect any effect
f treatment with an ACEI or an ARB. In contrast, the
IFE (Losartan Intervention For Endpoint Reduction in
ypertension) (29) and the VALUE (Valsartan Antihyper-
ensive Long-Term Use Evaluation) (30) trials, both testing
he effect of ARBs, detected significant reductions in the
ates of new-onset AF.
OST-MI. Two studies examined the effect of RAS inhibi-
ion on the development of AF after MI, both using
CEIs. When combining the evidence from these 2 stud-
es, no beneficial effect of ACEI treatment was detectable
verall (OR: 0.72; 95% CI: 0.41 to 1.27; p  0.26).
owever, these 2 studies came to disparate conclusions, also
ndicated by a significant test for heterogeneity (chi-square
est, p  0.03). In the larger study, the GISSI-3 (Gruppo
taliano per lo Studio Della Sopravvivenza Nell’Infarto
iocardico-3) study (31), no significant reductions in AF
ates were found over a follow-up period of 6 weeks by
isinopril treatment starting within the first 24 h after MI.
f note, most patients (84%) had no evidence of heart
ailure at the time of MI. In the smaller TRACE (Tran-
olapril Cardiac Evaluation) study (32), only subjects with
vidence of heart failure were included, and the follow-up
eriod was much longer (2 to 4 years). This study detected
significant and large reduction of 49% in the OR for
ew-onset AF after MI.
EART FAILURE. Three studies examined the effect of RAS
nhibition on AF in patients with heart failure. In the
mallest, SOLVD (Studies Of Left Ventricular Dysfunc-
ion) (33), the effect of the ACEI enalapril was examined,
hereas CHARM (Candesartan in Heart Failure: Assess-
ent of Reduction in Mortality and Morbidity) (34) and
al-HeFT (Valsartan Heart Failure Trial) (35) studied the
ffects of the ARBs candesartan and valsartan, respectively.
verall, there was a significant beneficial effect of RAS
nhibition (OR: 0.52; 95% CI: 0.31 to 0.87; p  0.01). All
individual trials demonstrated significant reductions in
ew-onset AF rates, although there was significant hetero-
eneity among the studies (chi-square test, p  0.0003).
OLVD, including patients with the most severely im- caired left ventricular systolic function among the 3 trials,
howed the largest reduction in AF rates (OR: 0.18),
hereas reductions in AF rates were more modest in
HARM (OR: 0.81) and Val-HeFT (OR: 0.63).
econdary prevention. AFTER CARDIOVERSION. Eight tri-
ls investigated the effects of RAS inhibition on the recur-
ence of AF after electrical or chemical cardioversion.
verall, there was a significant reduction in the risk for AF
ecurrence after cardioversion with the use of ACEIs or
RBs (OR: 0.55; 95% CI: 0.34 to 0.89; p  0.01). The
ajority of individual trials demonstrated beneficial effects.
he recently published GISSI-AF (Gruppo Italiano per lo
tudio Della Sopravvivenza Nell’Infarto Miocardico–Atrial
ibrillation) trial did not detect any effect of treatment with
alsartan on the recurrence of AF, which largely accounts
or the heterogeneity among studies in this particular
atient population (chi-square test, p  0.01).
Y MEDICAL THERAPY. Four studies examined the effects of
reatment with ACEIs or ARBs on the recurrence of AF in
atients with paroxysmal AF. Overall, there was a signifi-
ant reduction in the recurrence of AF with ACEI or ARB
reatment (OR: 0.37; 95% CI: 0.27 to 0.49; p  0.001). In
ontrast to the other subgroups, the 4 included studies were
omogeneous (chi-square test, p  0.49), and all 4 studies
ocumented large and significant reductions in the risk for
F by RAS inhibition.
UBANALYSIS EXCLUDING POST-HOC DATA. In secondary
revention, all included trials in the primary analysis had AF
re-specified as their primary end point (Table 1). In some
f the primary prevention trials, however, AF had not been
pre-specified outcome parameter. Excluding these trials,
he overall result in the hypertension group would still be
egative, with an OR of 0.89 (p  0.23), including all
tudies except HOPE. The hypertension studies then
ncluded would remain highly heterogeneous, with no
ffect in the older studies CAPPP and STOP-2 (AF
re-specified but detected only as an adverse event), no
ffect in TRANSCEND (AF pre-specified but the method
f AF detection not reported), and positive results in LIFE
nd VALUE (AF pre-specified and detected by yearly
lectrocardiography [ECG] at core laboratories). No studies
ould remain in the post-MI group, and 1 study would
emain in the heart failure group (CHARM, with a bene-
cial effect of RAS inhibition; OR: 0.85; p  0.05).
xcluding these trials with AF not being a pre-specified end
oint would not affect the overall results of the meta-
nalysis, as the overall reduction in the OR for AF would
emain at 33% (p 0.00001), although with a slightly wider
I (95% CI: 19% to 44%).
UBLICATION BIAS AND STUDY SELECTION. We refrained
rom using funnel plots, which can be misleading when
here is a real difference in effect sizes between studies with
igh precision and those with low precision (36). In our
ase, except for the GISSI-AF trial, most studies with high
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AF and RAS Inhibition May 25, 2010:2299–307recision were primary prevention trials, whereas studies
ith low precision were secondary prevention trials, and
ifferent treatment effect sizes between these populations
re likely. From the 5 trials showing the largest beneficial
ffect of RAS inhibition, 3 belonged to the group of the 5
mallest trials. Nonetheless, excluding these 5 trials from the
nalysis still resulted in a significant effect of RAS inhibition
n AF rates (OR: 0.77; 95% CI: 0.67 to 0.87; p  0.0001).
inally, for analysis of sensitivity, we repeated the meta-
nalysis after additional inclusion of the 6 studies not
ulfilling the criteria for the primary analysis. After includ-
ng these studies, the overall reduction in the OR for AF
as 35% (OR: 0.65; 95% CI: 0.56 to 0.76; p  0.00001).
hus, including these studies did not diminish the beneficial
ffect of RAS inhibition in our analysis.
iscussion
he results of the present meta-analysis based on 23
andomized controlled trials (RCTs) indicate that RAS
nhibition with either ACEIs or ARBs is effective in the
rimary and secondary prevention of AF. Our analysis
urther suggests that in the context of primary prevention,
atients with left ventricular hypertrophy and/or heart
ailure benefit most from RAS inhibition. In secondary
revention after cardioversion of persistent AF or medical
herapy for paroxysmal AF, RAS inhibition is overall
eneficial.
When considering new-onset AF in patients with arterial
ypertension, our analysis of 6 large clinical trials failed to
emonstrate any overall effect. These trials, however, were
ighly heterogeneous. In the 2 oldest trials, CAPPP (26)
nd STOP-2 (17), sensitivity and accuracy for the detec-
ion of new-onset AF may have suffered from AF being
scertained merely as an adverse event. HOPE (27) and
RANSCEND (28) were not “pure” hypertension trials
ut rather included subjects at high cardiovascular risk,
ith hypertension being 1 of several qualifying risk factors.
onetheless, these 2 trials included large numbers of pa-
ients with hypertension (50% in HOPE, 70% in
RANSCEND) but failed to detect any beneficial effects of
AS inhibition. In VALUE (30), hypertension was re-
uired as an inclusion criterion, and this study detected a
odest but significant reduction in new-onset AF from
.34% with amlodipine to 3.67% with valsartan. However,
his was at odds with blood pressure lowering per se, as the
lood pressure reduction was slightly greater in amlodipine-
reated patients than in valsartan-treated patients, suggest-
ng that mechanisms beyond blood pressure control may
ave contributed to the beneficial effects of valsartan. The
argest reduction of new-onset AF was found in the LIFE
tudy, from 5.28% in the atenolol group to 2.49% in the
osartan group, which was associated with a reduced risk for
ardiovascular morbidity and mortality, stroke, and hospi-
alization for heart failure for similar blood pressure reduc-
ion (37). The lower incidence of AF during treatment with Rosartan was associated with greater regression of left ven-
ricular hypertrophy and greater reduction of left atrial size
ompared to treatment with atenolol (38,39). Both left
entricular hypertrophy and left atrial volume are known to
e strong predictors of AF development (40,41). Although
eripheral blood pressure lowering was similar with losartan
nd atenolol, recent studies suggest that central blood
ressure lowering might be inadequate with atenolol be-
ause of unfavorable effects on arterial wave reflection (15).
hus, central hemodynamic factors could have contributed
o the disparate AF rates in the LIFE study. Also of note is
hat yearly ECG was performed only in the 2 studies with
ositive results. Less frequent ECG and in particular
nalyses based on adverse event rates may give dramatically
ifferent results as opposed to those based on yearly ECG:
n VALUE, no effect of valsartan on AF rates would be
etected if this analysis were based merely on adverse event
ates (42). Of final note, impaired detection of AF as an end
oint, as particularly the case in the older trials, most likely
ontributed to a more conservative estimate of the efficacy of
CEIs and ARBs (i.e., assuming the baseline randomiza-
ion process worked, not detecting an end point tends to
ead to type II error, resulting in no or less difference
etween active treatment and control, even though it is
iologically present). We believe that all available data
hould be used for the current analysis, but we also note that
he power to detect larger differences is low. However, more
ophisticated methods of detecting AF, such as telemoni-
oring or implantable loop recorders, can overcome this in
uture studies.
The impression gained from the hypertension trials that
atients with structural and/or functional cardiac abnormal-
ties derive the greatest benefit from RAS inhibition is
urther strengthened by the results of the 2 post-MI studies
nd the 3 heart failure trials. Of the 2 post-MI studies, only
RACE, which included patients with signs of heart failure
t the time of MI, detected a benefit of RAS inhibition with
randolapril (32), whereas GISSI-3 failed to detect a bene-
cial effect of lisinopril in post-MI patients without heart
ailure (31). Furthermore, all 3 individual trials in patients
ith heart failure were able to demonstrate a beneficial effect
f RAS inhibition on new-onset AF rates (33–35). Further
upporting the link between left ventricular dysfunction and
enefit from RAS inhibition, the effect was greatest in
OLVD (33), in which patients were randomized to either
nalapril or placebo and in which patients had the most
everely impaired left ventricular function among the 3 heart
ailure trials. However, it should also be noted that the lesser
ffect of additional therapy with an ARB seen in the more
ecent CHARM and Val-HeFT trials was most likely also
aused by the fact that a large number of patients were
lready receiving ACEIs as their standard therapy for heart
ailure.
As a main inclusion criterion of our analysis, all data,
ncluding those on primary prevention, were derived from
CTs. However, as a potential limitation of our analysis,
s
a
o
R
a
p
a
f
w
m
i
f
a
b
T
d
l
w
r
n
i
l
p
r
o
a
t
d
(
d
s
c
d
R
p
r
t
s
s
c
w
p
p
e
b
c
c
a
a
c
p
(
a
s
a
T
a
(
R
b
o
i
v
w
s
d
a
b
b
t
p
a
w
w
t
e
p
p
c
d
t
a
p
s
s
h
a
T
a
w
e
n
p
a
a
a
e
t
o
i
e
n
r
c
f
o
r
T
2305JACC Vol. 55, No. 21, 2010 Schneider et al.
May 25, 2010:2299–307 AF and RAS Inhibitionome of the reports on primary prevention were post hoc
nalyses, and AF was not a pre-specified end point. Because
f the large number of patients included in all identified
CTs, we believe that all RCTs should be considered in our
nalysis, not just those in which AF was a pre-specified end
oint and, as alluded to earlier, not just those with higher
ccuracy for the detection of AF. We hope that in the
uture, more primary prevention studies will be published
ith AF as a pre-specified end point and with more accurate
ethods for AF ascertainment. Of note, all of the studies
ncluded on secondary prevention, as discussed in the
ollowing text, pre-specified AF as their primary end point.
In the recurrence of AF after cardioversion, our meta-
nalysis showed a beneficial effect of RAS inhibition overall
ut with significant heterogeneity among individual studies.
he first report in post-cardioversion patients, from Van
en Berg et al. (43), demonstrated a beneficial effect of
isinopril, but this study was unique in that only patients
ith concurrent chronic heart failure were included. In the
emaining 7 trials, 5 demonstrated beneficial effects and 2
o effect. A potential cause for the lack of an effect of RAS
nhibition in these 2 post-cardioversion studies might be the
ow rates of concomitant use of antiarrhythmic drugs, in
articular amiodarone (44,45). Also, in GISSI-AF, the high
ate of concurrent ACEI use (57% of subjects) may have
bscured any potential effect of valsartan, as pointed out in
n editorial accompanying this study (46). Among the 5
rials in which a beneficial effect of RAS inhibition was
ocumented, 3 used amiodarone as concomitant treatment
47–49). Grecu et al. (50) used propafenone instead and
etected a beneficial effect of perindopril. In the most recent
tudy by Belluzzi et al. (51), cardioversion was achieved
hemically with propafenone. Even though antiarrhythmic
rugs were not used after cardioversion, a beneficial effect of
AS inhibition was detected, perhaps because the included
atients with lone AF were comparably healthy, and recur-
ence rates in the placebo group were relatively low (32%).
In the secondary prevention of AF by medical therapy,
he included studies were homogenous, with all individual
tudies finding beneficial effects of RAS inhibition. The
tudy by Yin et al. (19) in lone AF demonstrated that
ombinations of amiodarone with losartan or perindopril
ere more effective in preventing recurrence of AF com-
ared with amiodarone alone, with no difference between
erindopril and losartan. Perhaps the potent antiarrhythmic
ffects of amiodarone combine very favorably with the
eneficial effect of ACEIs and ARBs on atrial fibrosis and
onduction, but further experimental studies are required to
onfirm this. The unique aspect of this study was that left
trial diameters were also assessed, demonstrating that the
ddition of losartan or perindopril to amiodarone signifi-
antly attenuated the increase in left atrial diameter com-
ared with amiodarone alone. The 3 studies by Fogari et al.
18,52,53) focused on patients with arterial hypertension
nd used active comparator drugs. The first trial demon-
trated that recurrence rates are lower with losartan and imiodarone than with amlodipine and amiodarone (52).
he second compared the effects of valsartan, ramipril, and
mlodipine without concurrent treatment with amiodarone
18). A lower recurrence rate of AF was found with both
AS inhibitors compared with amlodipine despite similar
lood pressure lowering, again suggesting beneficial effects
f RAS inhibition beyond blood pressure control. Interest-
ngly, the beneficial effect was greater in patients receiving
alsartan compared with ramipril, which was associated
ith more favorable effects on P-wave dispersion. The third
tudy, in patients with hypertension and type 2 diabetes,
emonstrated that valsartan or amlodipine is superior to
tenolol or amlodipine, despite similar effects on peripheral
lood pressure (53). Again, this might not be true for central
lood pressure (15). Furthermore, this study showed that
he beneficial effects of valsartan or amlodipine were more
ronounced in those patients concurrently treated with
miodarone or propafenone compared with those treated
ith disopyramide or flecainide. More data in this group
ill be available after reporting of the ANTIPAF (Angio-
ensin II Antagonist in Paroxysmal Atrial Fibrillation) trial,
xamining the efficacy of olmesartan versus placebo in
atients with paroxysmal AF. The ANTIPAF trial will
rovide the first placebo-controlled data in the absence of
oncomitant therapy with antiarrhythmic drugs, and the
etection of AF in this study is being performed by
elemonitoring (54).
Our analysis also demonstrates similar benefits of ACEIs
nd ARBs overall, but analyses in specific subgroups were
recluded by too few data when separating ACEI and ARB
tudies. The hemodynamic effects of these drugs are very
imilar, and it might well be that ACEIs and ARBs also
ave similar effects on depolarization, fibrosis, and so on,
nd therefore similar overall efficacy in preventing AF.
here is, however, some evidence for disparate, direct
ntiarrhythmic effects among specific compounds, even
ithin drug classes. As an example, specific antiarrhythmic
ffects were found for the losartan metabolite EXP3174 but
ot for losartan itself or for captopril (55). Furthermore, the
reviously mentioned study by Yin et al. (19) seems to hint
t a slightly greater effect of perindopril over losartan on left
trial remodeling. Clearly, further research is needed in this
rea. We have already mentioned the issue of pre-defined
nd points, but considerable improvement is also needed in
he detection of AF in future clinical trials. Many episodes
f AF are clinically asymptomatic (56), and correspond-
ngly, AF-like symptoms correlate very poorly with true
pisodes of AF (57). For the assessment of true AF burden,
ew approaches, including telemetry and implantable loop
ecorders, are clearly superior to any assessment based on
linical symptoms (adverse event rates) or on more or less
requent ECG. Last but not least, we would like to point
ut that previous data from the LIFE trial (58) and first
esults from ACTIVE-I (Atrial Fibrillation Clopidogrel
rial With Irbesartan for Prevention of Vascular Events)ndicate that RAS inhibition reduces cardiovascular mor-
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AF and RAS Inhibition May 25, 2010:2299–307idity and mortality in patients with persistent AF. RAS
nhibition may therefore be effective across the full contin-
um of AF, from prevention of AF to reducing the
onsequences in those in whom sinus rhythm can no longer
e restored.
onclusions
ur meta-analysis demonstrates substantial benefits from
AS inhibition in the primary and secondary prevention of
F, supporting the concept of RAS inhibition as an
merging treatment option for the prevention of AF. In
rimary prevention, benefits were greatest in patients with
eft ventricular hypertrophy and/or heart failure, but it must
e acknowledged that some reports were based on post hoc
nalyses. In secondary prevention, the data suggest a bene-
cial effect of RAS inhibition after the cardioversion of
ersistent AF and in the medical prevention of paroxysmal
F. In secondary prevention, it also appears that RAS
nhibition was most effective when patients also received
miodarone. We also need more information on the effects
f ACEIs and ARBs on AF in the absence of concomitant
ntiarrhythmic therapy.
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nd Hypertension, Krankenhausstraße 12, 91054 Erlangen, Ger-
any. E-mail: roland.schmieder@uk-erlangen.de.
EFERENCES
1. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic
features of chronic atrial fibrillation: the Framingham study. N Engl
J Med 1982;306:1018–22.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial
fibrillation in adults: national implications for rhythm management
and stroke prevention: the Anticoagulation and Risk Factors in Atrial
Fibrillation (ATRIA) study. JAMA 2001;285:2370–5.
3. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural
remodeling during atrial fibrillation. Cardiovasc Res 2002;54:230–46.
4. Wachtell K. Atrial fibrillation, maybe it is not so lone? J Am Coll
Cardiol 2009;53:30–1.
5. Xiao HD, Fuchs S, Campbell DJ, et al. Mice with cardiac-restricted
angiotensin-converting enzyme (ACE) have atrial enlargement, car-
diac arrhythmia, and sudden death. Am J Pathol 2004;165:1019–32.
6. Goette A, Staack T, Rocken C, et al. Increased expression of
extracellular signal-regulated kinase and angiotensin-converting en-
zyme in human atria during atrial fibrillation. J Am Coll Cardiol
2000;35:1669–77.
7. Boldt A, Wetzel U, Weigl J, et al. Expression of angiotensin II
receptors in human left and right atrial tissue in atrial fibrillation with
and without underlying mitral valve disease. J Am Coll Cardiol
2003;42:1785–92.
8. Doronin SV, Potapova IA, Lu Z, Cohen IS. Angiotensin receptor type
1 forms a complex with the transient outward potassium channel
Kv4.3 and regulates its gating properties and intracellular localization.
J Biol Chem 2004;279:48231–7.
9. Chen YJ, Chen YC, Tai CT, Yeh HI, Lin CI, Chen SA. Angiotensin
II and angiotensin II receptor blocker modulate the arrhythmogenic
activity of pulmonary veins. Br J Pharmacol 2006;147:12–22.
0. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa
K. Angiotensin II antagonist prevents electrical remodeling in atrial
fibrillation. Circulation 2000;101:2612–7.1. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting
enzyme inhibition on the development of the atrial fibrillation sub-strate in dogs with ventricular tachypacing-induced congestive heart
failure. Circulation 2001;104:2608–14.
2. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling
and atrial fibrillation in experimental congestive heart failure. Cardio-
vasc Res 2002;54:456–61.
3. Boldt A, Scholl A, Garbade J, et al. ACE-inhibitor treatment
attenuates atrial structural remodeling in patients with lone chronic
atrial fibrillation. Basic Res Cardiol 2006;101:261–7.
4. von Lewinski D, Kockskamper J, Rubertus SU, et al. Direct pro-
arrhythmogenic effects of angiotensin II can be suppressed by AT(1)
receptor blockade in human atrial myocardium. Eur J Heart Fail
2008;10:1172–6.
5. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood
pressure-lowering drugs on central aortic pressure and clinical out-
comes: principal results of the Conduit Artery Function Evaluation
(CAFE) study. Circulation 2006;113:1213–25.
6. Palardy M, Ducharme A, Nattel S, et al. Absence of protective effect
of renin-angiotensin system inhibitors on atrial fibrillation develop-
ment: insights from the Canadian Trial of Atrial Fibrillation (CTAF).
Can J Cardiol 2008;24:709–13.
7. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old
and new antihypertensive drugs in elderly patients: cardiovascular
mortality and morbidity the Swedish Trial in Old Patients With
Hypertension-2 study. Lancet 1999;354:1751–6.
8. Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on
atrial fibrillation recurrence and P-wave dispersion in hypertensive
patients with recurrent symptomatic lone atrial fibrillation. Am J
Hypertens 2008;21:1034–9.
9. Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing
amiodarone vs. amiodarone plus losartan vs. amiodarone plus perin-
dopril for the prevention of atrial fibrillation recurrence in patients
with lone paroxysmal atrial fibrillation. Eur Heart J 2006;27:1841–6.
0. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
Trials 1986;7:177–88.
1. Fazio G, Pizzuto C, Sutera L, et al. Inefficiency of renin-angiotensin
inhibitors in preventing atrial fibrillation in patients with a normal
heart. Minerva Cardioangiol 2007;55:311–5.
2. Hirayama Y, Atarashi H, Kobayashi Y, et al. Angiotensin-converting
enzyme inhibitor therapy inhibits the progression from paroxysmal
atrial fibrillation to chronic atrial fibrillation. Circ J 2005;69:671–6.
3. Kawamura M, Ito H, Onuki T, et al. Combination therapy of renin
angiotensin system inhibitors and bepridil is useful for maintaining
sinus rhythm in patients with atrial fibrillation. J Cardiol 2007;50:
343–50.
4. Komatsu T, Ozawa M, Tachibana H, et al. Combination therapy with
amiodarone and enalapril in patients with paroxysmal atrial fibrillation
prevents the development of structural atrial remodeling. Int Heart J
2008;49:435–47.
5. Van Noord T, Crijns HJ, van den Berg MP, Van Veldhuisen DJ, Van
Gelder IC. Pretreatment with ACE inhibitors improves acute out-
come of electrical cardioversion in patients with persistent atrial
fibrillation. BMC Cardiovasc Disord 2005;5:3.
6. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-
converting-enzyme inhibition compared with conventional therapy on
cardiovascular morbidity and mortality in hypertension: the Captopril
Prevention Project (CAPPP) randomised trial. Lancet 1999;353:
611–6.
7. Salehian O, Healey J, Stambler B, et al. Impact of ramipril on the
incidence of atrial fibrillation: results of the Heart Outcomes Preven-
tion Evaluation study. Am Heart J 2007;154:448–53.
8. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor
blocker telmisartan on cardiovascular events in high-risk patients
intolerant to angiotensin-converting enzyme inhibitors: a randomised
controlled trial. Lancet 2008;372:1174–83.
9. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity
and mortality in the Losartan Intervention for Endpoint Reduction in
Hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359:995–1003.
0. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A,
Hua TA. Reduced incidence of new-onset atrial fibrillation with
angiotensin II receptor blockade: the VALUE trial. J Hypertens
2008;26:403–11.
33
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
K
r
2307JACC Vol. 55, No. 21, 2010 Schneider et al.
May 25, 2010:2299–307 AF and RAS Inhibition1. Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic
significance of atrial fibrillation in acute myocardial infarction: the
GISSI-3 data. Heart 2001;86:527–32.
2. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril
reduces the incidence of atrial fibrillation after acute myocardial
infarction in patients with left ventricular dysfunction. Circulation
1999;100:376–80.
3. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the
incidence of atrial fibrillation in patients with left ventricular dysfunc-
tion: insight from the Studies of Left Ventricular Dysfunction
(SOLVD) trials. Circulation 2003;107:2926–31.
4. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial
fibrillation in patients with symptomatic chronic heart failure by
candesartan in the Candesartan in Heart Failure: Assessment of
Reduction in Mortality and Morbidity (CHARM) program. Am
Heart J 2006;152:86–92.
5. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the
incidence of atrial fibrillation in patients with heart failure: results from
the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:
548–57.
6. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the
misleading funnel plot. BMJ 2006;333:597–600.
7. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor
blockade reduces new-onset atrial fibrillation and subsequent stroke
compared to atenolol: the Losartan Intervention for End Point
Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;
45:712–9.
8. Gerdts E, Wachtell K, Omvik P, et al. Left atrial size and risk of major
cardiovascular events during antihypertensive treatment: losartan in-
tervention for endpoint reduction in hypertension trial. Hypertension
2007;49:311–6.
9. Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocar-
diographic left ventricular hypertrophy and decreased incidence of
new-onset atrial fibrillation in patients with hypertension. JAMA
2006;296:1242–8.
0. Tsang TS, Barnes ME, Bailey KR, et al. Left atrial volume: important
risk marker of incident atrial fibrillation in 1655 older men and
women. Mayo Clin Proc 2001;76:467–75.
1. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic
predictors of nonrheumatic atrial fibrillation. The Framingham Heart
Study. Circulation 1994;89:724–30.
2. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis:
inhibition of renin-angiotensin system prevents new-onset atrial fibril-
lation. Am Heart J 2006;152:217–22.
3. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam
PJ, Lie KI. Effects of lisinopril in patients with heart failure and
chronic atrial fibrillation. J Card Fail 1995;1:355–63.
4. Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of
recurrent atrial fibrillation. N Engl J Med 2009;360:1606–17.
5. Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention
of relapsing atrial fibrillation. Int J Cardiol 2007;120:85–91. s6. Gillis AM. Angiotensin-receptor blockers for prevention of atrial
fibrillation—a matter of timing or target? N Engl J Med 2009;360:
1669–71.
7. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to
maintain sinus rhythm in patients with long-lasting persistent atrial
fibrillation: a prospective and randomized study. Circulation 2002;106:
331–6.
8. Madrid AH, Marin IM, Cervantes CE, et al. Prevention of recur-
rences in patients with lone atrial fibrillation. The dose-dependent
effect of angiotensin II receptor blockers. J Renin Angiotensin Aldo-
sterone Syst 2004;5:114–20.
9. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus
rhythm maintenance after external cardioversion of long-standing
persistent atrial fibrillation. Results of a prospective and controlled
study. Eur Heart J 2003;24:2090–8.
0. Grecu M, Olteanu RO, Olteanu SS, Georgescu CA. Does treatment
with ACE inhibitors prevent the long term recurrences of lone atrial
fibrillation after cardioversion? Rom J Intern Med 2007;45:29–33.
1. Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S.
Prevention of recurrent lone atrial fibrillation by the angiotensin-II
converting enzyme inhibitor ramipril in normotensive patients. J Am
Coll Cardiol 2009;53:24–9.
2. Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of
atrial fibrillation recurrence in hypertensive patients. J Cardiovasc
Pharmacol 2006;47:46–50.
3. Fogari R, Zoppi A, Mugellini A, et al. Comparative evaluation of
effect of valsartan/amlodipine and atenolol/amlodipine combinations
on atrial fibrillation recurrence in hypertensive patients with type 2
diabetes mellitus. J Cardiovasc Pharmacol 2008;51:217–22.
4. Goette A, Breithardt G, Fetsch T, et al. Angiotensin II Antagonist in
Paroxysmal Atrial Fibrillation (ANTIPAF) trial: rationale and study
design. Clin Drug Investig 2007;27:697–705.
5. Lynch JJ Jr, Stump GL, Wallace AA, et al. EXP3174, the AII
antagonist human metabolite of losartan, but not losartan nor the
angiotensin-converting enzyme inhibitor captopril, prevents the devel-
opment of lethal ischemic ventricular arrhythmias in a canine model of
recent myocardial infarction. J Am Coll Cardiol 1999;34:876–84.
6. Orlov MV, Ghali JK, Araghi-Niknam M, Sherfesee L, Sahr D,
Hettrick DA. Asymptomatic atrial fibrillation in pacemaker recipients:
incidence, progression, and determinants based on the atrial high rate
trial. Pacing Clin Electrophysiol 2007;30:404–11.
7. Quirino G, Giammaria M, Corbucci G, et al. Diagnosis of paroxysmal
atrial fibrillation in patients with implanted pacemakers: relationship
to symptoms and other variables. Pacing Clin Electrophysiol 2009;32:
91–8.
8. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity
and mortality in hypertensive patients with a history of atrial fibrilla-
tion: the Losartan Intervention for End Point Reduction in Hyper-
tension (LIFE) study. J Am Coll Cardiol 2005;45:705–11.
ey Words: atrial fibrillation y angiotensin y angiotensin type 1
eceptor y angiotensin-converting enzyme inhibitors y renin-angiotensin
ystem.
